Who are Placebo/Janagliflozin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oral hypoglycemic agents, Invokana Pill, Oral administration of Ipragliflozin, LG-group, Canagliflozin - SGLT2i, Weight Based Group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-janagliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo/Janagliflozin — Competitive Intelligence Brief

Placebo/Janagliflozin (Placebo/Janagliflozin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo/Janagliflozin (Placebo/Janagliflozin) — Sihuan Pharmaceutical Holdings Group Ltd.. Janagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo/Janagliflozin TARGET	Placebo/Janagliflozin	Sihuan Pharmaceutical Holdings Group Ltd.	phase 3	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
Invokana Pill	Invokana Pill	AgelessRx	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Oral administration of Ipragliflozin	Oral administration of Ipragliflozin	Asan Medical Center	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
LG-group	LG-group	Medical University of Vienna	marketed	SGLT2 inhibitor	SGLT2
Canagliflozin - SGLT2i	Canagliflozin - SGLT2i	Royal Devon and Exeter NHS Foundation Trust	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Weight Based Group	Weight Based Group	University of Colorado, Denver	marketed	SGLT2 inhibitor	SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo/Janagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-janagliflozin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab